Dimerization of FGFR4 mutants with enhanced kinase activity

Stable Identifier
R-HSA-2038946
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

FGFR4 is highly expressed in rhabdomyosarcoma (RMS) tissue, and high levels of expression are correlated with lower survival. Sequencing of exons from 94 RMS tumors identified 14 missense variants, 6 of which were localized in the tyrosine kinase domain, and four of which were in two amino acids (N535K/D and V550E/L). Mutations at amino acid 535 are predicted to eliminate an inhibitory H-bond that restricts receptor autophosphorylation, and mutations at amino acid 550 are believed to alter the ATP-binding site. Functional studies on N535K and V550 show that they undergo autophosphorylation when transfected into a murine RMS lines and transformed NIH 3T3 cells, leading to a metastatic phenotype (Taylor, 2009).

Literature References
PubMed ID Title Journal Year
19809159 Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models

Taylor JG, 6th, Cheuk, AT, Tsang, PS, Chung, JY, Song, YK, Desai, K, Yu, Y, Chen, QR, Shah, K, Youngblood, V, Fang, J, Kim, S, Yeung, C, Helman, LJ, Mendoza, A, Ngo, V, Staudt, LM, Wei, JS, Khanna, C, Catchpoole, D, Qualman, SJ, Hewitt, SM, Merlino, G, Chanock, SJ, Khan, J

J Clin Invest 2009
Participants
Participant Of
Normal reaction
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
rhabdomyosarcoma 3247 Rhabdomyosarcoma NOS (morphologic abnormality), rhabdomyosarcoma, Rhabdomyosarcoma, no subtype (morphologic abnormality), rhabdomyoblastoma, Rhabdomyosarcoma (disorder)
Authored
Reviewed
Created
Cite Us!